Frog-derived gut bacterium eradicates tumors in mice
A preclinical study reports that a frog-derived strain of the gut bacterium *Ewingella americana* can eliminate colorectal tumors in mice by colonizing hypoxic tumor tissue and triggering a strong immune response. Commenters find the underlying peer‑reviewed work interesting but emphasize that curing cancer in mouse models is common and rarely translates cleanly to humans, especially given issues like fragile artificial tumors and immunocompromised patients. Many are also wary of the sensationalist blog amplifying the result, pointing to its history of conspiracy content and stressing the need for better sources and larger, longer-term studies before claiming a breakthrough.
Study results & proposed mechanism
- Mouse study showed a frog-derived strain of Ewingella americana causing in vivo regression/eradication of colorectal tumors.
- Only 1 of 9 tested bacteria worked this well; 3 facultative anaerobes showed regression, with the frog-derived strain strongest.
- Mechanism discussed: facultative anaerobes preferentially colonize hypoxic, immunosuppressive tumor microenvironments, proliferate inside tumors, then trigger a strong immune response (T/B cells, neutrophils, inflammatory cytokines) that destroys tumor plus bacteria.
- Commenters emphasize this is essentially a clever form of immunotherapy, not something completely outside that category.
Mouse models vs human relevance
- Many stress the “in mice” caveat: curing induced mouse tumors is common and expected before a therapy is considered for further evaluation.
- Mouse tumors here were small, recently implanted, and treated early; follow-up was ~40–60 days, too short to know about recurrence or hidden metastases.
- Real human tumors are older, heterogeneous, and have evolved better immune evasion; translation rate from mice to humans is said to be “low single digit percent.”
- Some still see it as promising, arguing that even months of remission can matter clinically.
Safety, patient profile & constraints
- Case report linked: E. americana sepsis in an immunocompromised chemo patient.
- Study assumes immunocompetent mice, whereas many cancer patients are immunocompromised, which may limit applicability or safety.
- Several warn explicitly not to self-administer this bacterium; the effective strain is specific and systemic infection is a real risk.
Source quality & framing
- The Substack/blog is heavily criticized as sensationalist, conspiratorial, and “AI slop,” though the underlying NIH-linked paper is acknowledged as real.
- Some consider posting the blog instead of primary sources as spammy or misleading.
Broader reflections & tangents
- Discussion branches into: historical bacterial cancer therapies (e.g., Coley’s toxins), beneficial uses of microbes, and potential future use of viruses.
- Long digression debates capitalism, environmental destruction, and ecosystem loss (including frogs), with conflicting views on whether technology can “fix” what’s being damaged.
- Thread contains substantial humor: xkcd, Hitchhiker’s Guide mice, Sean Connery/Zardoz references, and recurring jokes about how often mice “get” miracle cures.